Lion Biotechnologies Names Elma Hawkins President, Chief Executive Officer and Director Read more about Lion Biotechnologies Names Elma Hawkins President, Chief Executive Officer and Director
Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH Read more about Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH
Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering Read more about Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering
Lion Biotechnologies Announces Closing of Underwritten Common Stock Offering Read more about Lion Biotechnologies Announces Closing of Underwritten Common Stock Offering
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma Read more about Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma
Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research Read more about Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research
Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications Read more about Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications
Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma Read more about Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma Read more about Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology Read more about Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology